The University of Southampton
University of Southampton Institutional Repository

Idiopathic pulmonary fibrosis in the United Kingdom: findings from the first decade of the largest single-country IPF registry

Idiopathic pulmonary fibrosis in the United Kingdom: findings from the first decade of the largest single-country IPF registry
Idiopathic pulmonary fibrosis in the United Kingdom: findings from the first decade of the largest single-country IPF registry
Introduction: Idiopathic Pulmonary Fibrosis (IPF) is the most common progressive interstitial lung disease (ILD) and has a dismal prognosis. We reviewed data from the UK ILD Registry and present changes over time.

Methods: participating centres entered data onto a central electronic database between 1 January 2013 and 19 February 2023. Informed consent was obtained by all participants. A descriptive analysis of these data was undertaken.

Results: data were available from 5052 cases from 87 centres. There was a male preponderance (77.8%) with mean age of 74.0 years (± 8.1). Overall, 66% of patients were ex-smokers and 76% had at least one co-morbidity. Over a third (36.7%) experienced a delay of more than 24 months before first clinic visit, and the average wait time from referral to first clinic visit was 96 days (for the last 12 months of data collection this rose to 100 days). At first clinic visit almost all patients had GAP Stage I (63%) or Stage II (36%) disease, with only 1% having Stage III. Pirfenidone (approved for use in April 2013) was initially used in around a third of cases, with its use dropping by around 10 percentage points after nintedanib was approved in January 2016. As pirfenidone use dropped nintedanib use rose from 6.7% in 2013 to 31.5% in 2022. At presentation 7.5% were recruited to a clinical trial, rising to 21.7% of cases at any time during follow up.

Conclusion: these data reflect clinical practice across ILD centres in the UK and show changes of care over the last decade. We have shown increasing use of antifibrotic therapy but a persistent delay in referral to clinic review. Greater service provision is required for these patients.
0903-1936
Fahim, Ahmed
5e17b7c8-cb7a-4c99-9503-51a3f009ac28
Loughenbury, Maria
85af36f5-03e9-451c-917b-8a6eeb7084ab
Agnew, Sarah
1cc0710a-3326-4119-8979-1e90954ff8b3
Fletcher, Sophie
71599088-9df7-4d4a-8570-aef773ead0fe
et al.
Fahim, Ahmed
5e17b7c8-cb7a-4c99-9503-51a3f009ac28
Loughenbury, Maria
85af36f5-03e9-451c-917b-8a6eeb7084ab
Agnew, Sarah
1cc0710a-3326-4119-8979-1e90954ff8b3
Fletcher, Sophie
71599088-9df7-4d4a-8570-aef773ead0fe

Fahim, Ahmed, Loughenbury, Maria and Agnew, Sarah , et al. (2024) Idiopathic pulmonary fibrosis in the United Kingdom: findings from the first decade of the largest single-country IPF registry. European Respiratory Journal, 64. (doi:10.1183/13993003.congress-2024.PA5147).

Record type: Meeting abstract

Abstract

Introduction: Idiopathic Pulmonary Fibrosis (IPF) is the most common progressive interstitial lung disease (ILD) and has a dismal prognosis. We reviewed data from the UK ILD Registry and present changes over time.

Methods: participating centres entered data onto a central electronic database between 1 January 2013 and 19 February 2023. Informed consent was obtained by all participants. A descriptive analysis of these data was undertaken.

Results: data were available from 5052 cases from 87 centres. There was a male preponderance (77.8%) with mean age of 74.0 years (± 8.1). Overall, 66% of patients were ex-smokers and 76% had at least one co-morbidity. Over a third (36.7%) experienced a delay of more than 24 months before first clinic visit, and the average wait time from referral to first clinic visit was 96 days (for the last 12 months of data collection this rose to 100 days). At first clinic visit almost all patients had GAP Stage I (63%) or Stage II (36%) disease, with only 1% having Stage III. Pirfenidone (approved for use in April 2013) was initially used in around a third of cases, with its use dropping by around 10 percentage points after nintedanib was approved in January 2016. As pirfenidone use dropped nintedanib use rose from 6.7% in 2013 to 31.5% in 2022. At presentation 7.5% were recruited to a clinical trial, rising to 21.7% of cases at any time during follow up.

Conclusion: these data reflect clinical practice across ILD centres in the UK and show changes of care over the last decade. We have shown increasing use of antifibrotic therapy but a persistent delay in referral to clinic review. Greater service provision is required for these patients.

This record has no associated files available for download.

More information

e-pub ahead of print date: 30 October 2024
Published date: 30 October 2024

Identifiers

Local EPrints ID: 504223
URI: http://eprints.soton.ac.uk/id/eprint/504223
ISSN: 0903-1936
PURE UUID: 9d0c5edb-18ae-4426-9802-19b4fa6d2284
ORCID for Sophie Fletcher: ORCID iD orcid.org/0000-0002-5633-905X

Catalogue record

Date deposited: 01 Sep 2025 16:34
Last modified: 02 Sep 2025 02:17

Export record

Altmetrics

Contributors

Author: Ahmed Fahim
Author: Maria Loughenbury
Author: Sarah Agnew
Author: Sophie Fletcher ORCID iD
Corporate Author: et al.

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×